Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients. Our two most advanced programs include a diabetes treatment candidate and a cosmetic skin lightening agent.
Our sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and in Europe (November 2013). We have begun partnering discussions to review options for the outlicensing of our SGLT inhibitor. A pharmaceutical partner would handle the downstream clinical and commercial needs of our program.
Recognized for the scientific innovation at our laboratory in France, the French government awarded our team an innovation grant worth CDN$1.9 Million to develop our cosmetic skin lightener program to a commercial ready stage. Several efficacy and stability studies have been completed with results showing superiority over popular commercial products. Further toxicity studies are underway.
Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.
More recently, Sirona has teamed up with Bloom Burton (www.bloomburton.com), Canada’s leading healthcare-specialized investment banking group, to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.